Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2075561

Female Infertility - Pipeline Review, H1 2012

Description:
Female Infertility – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Female Infertility - Pipeline Review, H1 2012', provides an overview of the Female Infertility therapeutic pipeline. This report provides information on the therapeutic development for Female Infertility, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Infertility. 'Female Infertility - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Female Infertility.
- A review of the Female Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Female Infertility pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Female Infertility.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Female Infertility pipeline depth and focus of Female Infertility therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Female Infertility Therapeutic Products under Development, Key Players in Female Infertility Therapeutics, Female Infertility Pipeline Overview, Female Infertility Pipeline, Female Infertility Pipeline Assessment
 
Contents:


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Infertility Overview
Therapeutics Development
An Overview of Pipeline Products for Female Infertility
Female Infertility Therapeutics under Development by Companies
Female Infertility Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Female Infertility Therapeutics – Products under Development by Companies
Female Infertility Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Female Infertility Therapeutics Development
Abbott Laboratories
Vyteris, Inc.
Watson Pharmaceuticals, Inc.
Merck & Co., Inc.
Euroscreen S.A.
Takeda Pharmaceutical Company Limited
ASKA Pharmaceutical Co., Ltd
Astellas Pharma Inc.
Dong-A Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Limited
Zydus Cadila Healthcare Limited
Pantec Biosolutions AG
Merck KGaA
Access Pharmaceuticals, Inc.
Addex Pharmaceuticals
AEterna Zentaris Inc.
Soligenix, Inc.
Repros Therapeutics Inc.
Protalix BioTherapeutics, Inc.
Glycotope GmbH
Peptron, Inc.
Meditrina Pharmaceuticals, Inc.
PregLem SA
Ferring Pharmaceuticals, Inc.
Isifer AB
Female Infertility – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AEZS-115 - Drug Profile
TAK-385 - Drug Profile
Anastrozole - Drug Profile
Elagolix - Drug Profile
ADX68692 - Drug Profile
GnRH Antagonists - Drug Profile
GnRH Patch - Drug Profile
Proellex - Drug Profile
Recombinant Hormones For Ovulation Induction - Drug Profile
LPM Leuprolide - Drug Profile
PRX-111 - Drug Profile
Fertility Hormone - Drug Profile
Drugs For Prostate Cancer & Endometriosis - Drug Profile
JR-041 - Drug Profile
JR-041 - Drug Profile
PGL1001 - Drug Profile
PGL2001 - Drug Profile
PGL3001 - Drug Profile
ESN-364 - Drug Profile
OCP - Drug Profile
Elonva - Drug Profile
DA-3803 - Drug Profile
Metformin - Drug Profile
Raloxifene - Drug Profile
Letrozole - Drug Profile
Human Chorionic Gonadotropin - Drug Profile
Clomiphene Citrate - Drug Profile
Human Chorionic Gonadotropin + Clomiphene Citrate - Drug Profile
Leuprolide Acetate - Drug Profile
Microdose GnRh Agonist - Drug Profile
Metformin - Drug Profile
Metformin - Drug Profile
MPI-676 - Drug Profile
Metformin - Drug Profile
Aldactone - Drug Profile
Progesterone - Drug Profile
Synthetic Gonadotropin Releasing Hormone - Drug Profile
XM17 - Drug Profile
D-chiro-inositol - Drug Profile
Simvastatin - Drug Profile
Dexamethasone + Recombinant hCG - Drug Profile
GnRH agonist - Drug Profile
KLH-2109 - Drug Profile
Femara - Drug Profile
Neupogen - Drug Profile
Recombinant Follicle Stimulating Hormone - Drug Profile
Metformin + Clomiphene - Drug Profile
Tamoxifen + Clomiphene - Drug Profile
Prod 5 - Drug Profile
Flutamide + Metformin - Drug Profile
Heparin - Drug Profile
Clomiphene Citrate + Dexamethasone - Drug Profile
Medroxyprogesterone - Drug Profile
Metformin - Drug Profile
Aspirin - Drug Profile
Oral Infertility Drugs - Drug Profile
DR-2011 - Drug Profile
Afolia - Drug Profile
ASP1707 - Drug Profile
Neupogen - Drug Profile
Isifera - Drug Profile
Endole - Drug Profile
FSH-GEX - Drug Profile
AKP-501 - Drug Profile
IVF001 - Drug Profile
IVF002 - Drug Profile
Prod 6 - Drug Profile
Female Infertility Therapeutics – Drug Profile Updates
Female Infertility Therapeutics – Discontinued Products
Female Infertility Therapeutics - Dormant Products
Female Infertility – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Female Infertility, H1 2012
Products under Development for Female Infertility – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Abbott Laboratories, H1 2012
Vyteris, Inc., H1 2012
Watson Pharmaceuticals, Inc., H1 2012
Merck & Co., Inc., H1 2012
Euroscreen S.A., H1 2012
Takeda Pharmaceutical Company Limited, H1 2012
ASKA Pharmaceutical Co., Ltd, H1 2012
Astellas Pharma Inc., H1 2012
Dong-A Pharmaceutical Co., Ltd., H1 2012
Kissei Pharmaceutical Co., Ltd., H1 2012
Teva Pharmaceutical Industries Limited, H1 2012
Zydus Cadila Healthcare Limited, H1 2012
Pantec Biosolutions AG, H1 2012
Merck KGaA, H1 2012
Access Pharmaceuticals, Inc., H1 2012
Addex Pharmaceuticals, H1 2012
AEterna Zentaris Inc., H1 2012
Soligenix, Inc., H1 2012
Repros Therapeutics Inc., H1 2012
Protalix BioTherapeutics, Inc., H1 2012
Glycotope GmbH, H1 2012
Peptron, Inc., H1 2012
Meditrina Pharmaceuticals, Inc., H1 2012
PregLem SA, H1 2012
Ferring Pharmaceuticals, Inc., H1 2012
Isifer AB, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Female Infertility Therapeutics – Drug Profile Updates
Female Infertility Therapeutics – Discontinued Products
Female Infertility Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Female Infertility, H1 2012
Products under Development for Female Infertility – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/2075561

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Jul 28th 2014
1:53:41 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Female Infertility - Pipeline Review, H1 2012

Web Address

http://www.researchandmarkets.com/reports/2075561

Office Code

OC8DIMPLLMTUQU

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 500
Electronic (PDF) - Site License USD 1,000
Electronic (PDF) - Enterprisewide USD 1,500

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Jul 28th 2014
1:53:41 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)